Evaluation of [18F]MK-0911, a positron emission tomography (PET) tracer for opioid receptor-like 1 (ORL1), in rhesus monkey and human

NeuroImage

Volumn 68, Issue , 2013, Pages 1-10

  Hostetler, Eric D ^a   Sanabria Bohórquez, Sandra ^a   Eng, Waisi ^a   Joshi, Aniket D ^a   Patel, Shailendra ^a   Gibson, Raymond E ^a   O'Malley, Stacey ^a   Krause, Stephen M ^a   Ryan, Christine ^a   Riffel, Kerry ^a   Bi, Sheng ^a   Okamoto, Osamu ^b   Kawamoto, Hiroshi ^b   Ozaki, Satoshi ^b   Ohta, Hisashi ^b   de Groot, Tjibbe ^c   Bormans, Guy ^c   Depré, Marleen ^c   de Hoon, Jan ^c   De Lepeleire, Inge ^d   Reynders, Tom ^d   Cook, Jacquelynn J ^a   Burns, H Donald ^a   Egan, Michael ^e   Cho, William ^e   van Laere, Koen ^c   Hargreaves, Richard J ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b Tsukuba Research Institute   (Japan)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Merck Sharp and Dohme   (Belgium)

^e Merck Clinical Pharmacology   (United States)

Author keywords

Fluorine 18; Human; Monkey; NOP; Opioid receptor like 1; PET

Indexed keywords

FLUORINE MK 0911 F 18; OPIATE RECEPTOR; OPIOID RECEPTOR LIKE 1; TRACER; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; FLUORINE; MK 0911; MK-0911; NOCICEPTIN RECEPTOR; PIPERIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; BRAIN SLICE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; GRAY MATTER; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMAGE ANALYSIS; IN VIVO STUDY; ISOTOPE LABELING; LIMIT OF QUANTITATION; MALE; NEUROIMAGING; NONHUMAN; NORMAL HUMAN; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; RADIORECEPTOR ASSAY; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; RHESUS MONKEY; STRUCTURE ANALYSIS; ANIMAL; BRAIN; CHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; SCINTISCANNING; TISSUE DISTRIBUTION;

ADULT; ANIMALS; BENZIMIDAZOLES; BRAIN; FLUORINE RADIOISOTOPES; HUMANS; MACACA MULATTA; MALE; MIDDLE AGED; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, OPIOID; TISSUE DISTRIBUTION; YOUNG ADULT;

MLCS; MLOWN;

EID: 84871650857     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.11.053     Document Type: Article

References (28)

1. Ardati A., Henningsen R.A., Higelin J., Reinscheid R.K., Civelli O., Monsma F.J. Interaction of [H-3]orphanin FQ and I-125-Tyr14-orphanin FQ with the orphanin FQ receptor: kinetics and modulation by cations and guanine nucleotides. Mol. Pharmacol. 1997, 51:816-824.
2. Berthele A., Platzer S., Dworzak D., Schadrack J., Mahal B., Buttner A., Assmus H.P., Wurster K., Zieglgansberger W., Conrad B., Tolle T.R. [H-3]Nociceptin ligand-binding and nociceptin opioid receptor mRNA expression in the human brain. Neuroscience 2003, 121:629-640.
3. Bridge K.E., Wainwright A., Reilly K., Oliver K.R. Autoradiographic localization of I-125[tyr(14)] nociceptin/orphanin FQ binding sites in macaque primate CNS. Neuroscience 2003, 118:513-523.
4. Chen Y., Fan Y., Liu J., Mestek A., Tian M.T., Kozak C.A., Yu L. Molecular-cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett. 1994, 347:279-283.
5. Dohta Y., Yamashita T., Horiike S., Nakamura T., Fukami T. A system for LogD screening of 96-well plates using a water-plug aspiration/injection method combined with high-performance liquid chromatography-mass Spectrometry. Anal. Chem. 2007, 79:8312-8315.
6. Fukuda K., Kato S., Mori K., Nishi M., Takeshima H., Iwabe N., Miyata T., Houtani T., Sugimoto T. cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett. 1994, 343:42-46.
7. Hamill T.G., Sato N., Jitsuoka M., Tokita S., Sanabria S., Eng W., Ryan C., Krause S., Takenaga N., Patel S., Zeng Z.Z., Williams D., Sur C., Hargreaves R., Burns H.D. Inverse agonist histamine H3 receptor PET tracers labelled with carbon-11 or fluorine-18. Synapse 2009, 63:1122-1132.
8. Hostetler E.D., Hamill T., Francis B.E., Burns H.D. A versatile, commercially available automated synthesizer for the development and production of PET radiotracers. J. Label. Compd. Radiopharm. 2001, 44:S1042-S1044.
9. Jin H., Di L. Permeability-in vitro assays for assessing drug transporter activity. Curr. Drug Metab. 2008, 9:911-920.
10. 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors. J. Nucl. Med. 2011, 52:1638-1645.
11. Kobayashi K., Uchiyama M., Takahashi H., Kawamoto H., Ito S., Yoshizumi T., Nakashima H., Kato T., Shimizu A., Yamamoto I., Asai M., Miyazoe H., Ohno A., Hirayama M., Ozaki S., Tani T., Ishii Y., Tanaka T., Mochidome T., Tadano K., Fukuroda T., Ohta H., Okamoto O. 2-Cyclohexylcarbonylbenzimidazoles as potent, orally available and brain-penetrable opioid receptor-like 1 (ORL1) antagonists. Bioorg. Med. Chem. Lett. 2009, 19:3096-3099.
12. Lambert D.G. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat. Rev. Drug Discov. 2008, 7:694-710.
13. Lammertsma A.A., Hume S.P. A simplified reference tissue model for PET receptor studies. Neuroimage 1996, 4:153-158.
14. 11C-NOP-1A. J. Nucl. Med. 2012, 53:385-392.
15. 11C]NOP-1A, a new PET radioligand to image nociceptin/orphanin FQ peptide (NOP) receptors in healthy subjects. J. Cereb. Blood Flow Metab. 2012, 32:S134.
16. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995, 377:532-535.
17. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., Caput D., Vassart G., Meunier J.C. ORL1, a novel member of the opioid receptor family-cloning, functional expression and localization. FEBS Lett. 1994, 341:33-38.
18. 11C]methyl-Ro 64-6198 as an ORL1 receptor imaging agent. Nucl. Med. Biol. 2001, 28:941-947.
19. Ogawa M., Hatano K., Kawasumi Y., Ishiwata K., Kawamura K., Ozaki S., Ito K. Synthesis and evaluation of 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-[C-11]ethyl-1,3-dihydro-2H-benzimidazol-2-one as a brain ORL1 receptor imaging agent for positron emission tomography. Nucl. Med. Biol. 2003, 30:51-59.
20. Pike V.W., Rash K.S., Chen Z.G., Pedregal C., Statnick M.A., Kimura Y., Hong J., Zoghbi S.S., Fujita M., Toledo M.A., Diaz N., Gackenheimer S.L., Tauscher J.T., Barth V.N., Innis R.B. Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography. J. Med. Chem. 2011, 54:2687-2700.
21. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J., Civelli O. Orphanin-FQ-a neuropeptide that activates an opioid-like G-protein-coupled receptor. Science 1995, 270:792-794.
22. Sanabria-Bohorquez S.M., Biver F., Damhaut P., Wikler D., Veraart C., Goldman S. Quantification of 5-HT1A receptors in human brain using p-MPPF kinetic modelling and PET. Eur. J. Nucl. Med. 2002, 29:76-81.
23. Satoh A., Sagara T., Sakoh H., Hashimoto M., Nakashima H., Kato T., Goto Y., Mizutani S., Azuma-Kanoh T., Tani T., Okuda S., Okamoto O., Ozaki S., Iwasawa Y., Ohta H., Kawamoto H. Identification of an orally active opioid receptor-like 1 (ORL1) receptor antagonist 4-{3-[(2R)-2,3-dihydroxypropyl]-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl}-1-[(1S,3S,4R)-spiro[bicyclo[2.2.1]heptane-2,1'-cyclopropan]-3-ylmethyl]piperidine as clinical candidate. J. Med. Chem. 2009, 52:4091-4094.
24. 18F-labeled inverse agonist radioligands. J. Nucl. Med. 2010, 51:112-120.
25. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imaging Biol. 2003, 5:376-389.
26. Yamazaki M., Neway W.E., Ohe T., Chen I.W., Rowe J.F., Hochman J.H., Chiba M., Lin J.H. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 2001, 296:723-735.
27. Yoshizumi T., Takahashi H., Miyazoe H., Sugimoto Y., Tsujita T., Kato T., Ito H., Kawamoto H., Hirayama M., Ichikawa D., Azuma-Kanoh T., Ozaki S., Shibata Y., Tani T., Chiba M., Ishii Y., Okuda S., Tadano K., Fukuroda T., Okamoto O., Ohta H. A novel class of cycloalkano[b]pyridines as potent and orally active opioid receptor-like 1 antagonists with minimal binding affinity to the hERG K+ channel. J. Med. Chem. 2008, 51:4021-4029.
28. Zhang M.R., Furutsuka K., Yoshida Y., Suzuki K. How to increase the reactivity of [F-18]fluoroethyl bromide: [F-18]fluoroethylation of amine, phenol and amide functional groups with [F-18]FEtBr, [F-18]FEtBr/NaI and [F-18]FEtOTf. J. Label. Compd. Radiopharm. 2003, 46:587-598.